MUSINOSUM, ENDOMETRIOID, DAN SEL JERNIH AMANDA...

56

DAFTAR PUSTAKA

Bologna-Molina, R., Mosqueda-Taylor, A., Molina-Frechero,

N., Mori-Estevez, A.D., Sánchez-Acuña G., 2013.

Comparison of The Value of PCNA and Ki-67 as Markers

of Cell Proliferation in Ameloblastic tumors. Medicina

Oral, Patologia Oral y Cirugia Bucal, 18(2). Pp: e174-

e179.

Chen, V.W., Ruiz, B., Killeen, J.L., Coté, T.R., Wu,

X.C., Correa, C.N., 2003. Pathology and Classification

of Ovarian Tumors. Cancer, 97(10 Suppl), pp.2631–2642.

Davis, M. et al., 2014. Comparison of Clinical Outcomes

of Patients with Clear Cell and Endometrioid Ovarian

Cancer Associated with Endometriosis to Papillary

Serous Carcinoma of The Ovary. Gynecologic Oncology,

132(3), pp.760–766.

De Azambuja, E. et al., 2007. Ki-67 as Prognostic Marker

in Early Breast Cancer: A Meta-analysis of Published

Studies Involving 12,155 Patients. British Journal of

Cancer, 96(10), pp.1504–1513.

Funk, J.O., Waga, S., Harry, J.B., Espling, E., Stillman,

B., Galloway, D., 1997. Inhibition of CDK Activity and

PCNA-dependent DNA Replication p21 is Blocked by

Interaction with The HPV-16 E7 Oncoprotein. Genes and

Development, 11(16), pp.2090–2100.

Gadducci, A. et al., 2009. Serum and Tissue Biomarkers as

Predictive and Prognostic Variables in Epithelial

Ovarian Cancer. Critical Reviews in

Oncology/Hematology, 69(1), pp.12–27.

Georgescu, C. V., Florescu, M., Simionescu, C., 1999.

Value of Immunohistochemistry in Confirming

Undifferentiated Ovarian Carcinomas. Romanian Journal

of Morphology and Embryology = Revue Roumaine de

Morphologie et Embryologie, 45, pp.133–142.

PERBEDAAN EKSPRESI KI-67 DAN PCNA PADA KANKER OVARIUM EPITELIAL TIPE SEROSUM,MUSINOSUM,ENDOMETRIOID, DAN SEL JERNIHAMANDA SARI PUSPITAUniversitas Gadjah Mada, 2015 | Diunduh dari http://etd.repository.ugm.ac.id/

57

Giurgea, L.N., Ungureanu, C., Mihailovici, M.S., 2012.

The Immunohistochemical Expression of p53 and Ki67 in

Ovarian Epithelial Borderline Tumors. Correlation with

Clinicopathological Factors. Romanian Journal of

Morphology and Embryology, 53(4), pp.967–973.

Guzińska-Ustymowicz, K., Pryczynicz, A., Kemona, A.,

Czyzewska, J., 2009. Correlation Between Proliferation

Markers: PCNA, Ki-67, MCM-2 and Antiapoptotic Protein

Bcl-2 in Colorectal Cancer. Anticancer Research,

29(8), pp.3049–3052.

Hamilton, W., Peters, T.J., Bankhead, C., Sharp, D.,

2009. Risk of Ovarian Cancer in Women with Symptoms in

Primary Care: Population Based Case-control Study. BMJ

(Clinical research ed.), 339, pp.b2998.

Hayat,M.A., 2010. Ovarian Cancer. Methods of Cancer

Diagnosis, Therapy, and Prognosis, 6, pp.5-9.

Jonat, W. & Arnold, N., 2011. Is the Ki-67 Labelling

Index Ready for Clinical Use? Annals of Oncology,

22(3), pp.500–502.

Jones, R.L. et al., 2009. The Prognostic Significance of

Ki67 Before and After Neoadjuvant Chemotherapy in

Breast Cancer. Breast Cancer Research and Treatment,

116(1), pp.53–68.

Junquiera, L.C., Caeneiro, J. 2005. Basic Histology Text

and Atlas. McGraw Hill. United States.

Karuppayil, S.M., Moran, E., Gokul, M., 1998.

Differential Regulation of p53-dependent and -

independent Proliferating Cell Nuclear Antigen Gene

Transcription by 12 S E1A Oncoprotein Requires CBP.

The Jurnal of Biological Chemistry, 273(28), pp.17303–

17306.

Klintman, M., Bendahl, P.O., Grabau, D., Lövgren, K.,

Malmström, P., Fernö, M., 2010. The Prognostic Value

of Ki67 is Dependent on Estrogen Receptor Status and

Histological Grade in Premenopausal Patients with


58

Node-negative Breast Cancer. Modern pathology: An

Official Journal of The United States and Canadian

Academy of Pathology, Inc, 23(2), pp.251–259.

Köbel, M. et al., 2008. Ovarian Carcinoma Subtypes are

Different Diseases: Implications for Biomarker

Studies. PLoS Medicine, 5(12), pp.1749–1760.

Komiyama, S.I., Aoki, D., Katsuki, Y., Nozawa, S., 2006.

Proliferative Activity of Early Ovarian Clear Cell

Adenocarcinoma Depends On Association with

Endometriosis. European Journal of Obstetrics

Gynecology and Reproductive Biology, 127(1), pp.130–

136.

Korkolopoulou, P., Oates, J., Kittas, C., Crocker, J.,

1994. p53, c-myc p62 and Proliferating Cell Nuclear

Antigen (PCNA) Expression in Non-Hodgkin's Lymphomas.

Journal of Clinical Pathology, 47, pp.9–14.

Kumar, V., Abbas, A. K., Aster J. C., 2013. Female

Genital System and Breast. Robbins and Cotran

Pathologic Basic of Disease. 9 edn. Elsevier Saunder,

Philadelphia, pp.695-698.

Kurman, R. & Shih, I., 2010. The Origin and Pathogenesis

of Epithelial Ovarian Cancer- A Proposed Unifying

Theory. The American Journal of Surgical Pathology,

34(3), pp.433–443.

Levanon, K., Crum, C., Drapkin, R., 2008. New Insights

Into The Pathogenesis of Serous Ovarian Cancer and Its

Clinical Impact. Journal of Clinical Oncology, 26(32),

pp.5284–5293.

Le Page, C., Huntsman, D.G., Provencher, D.M., Mes-

Masson, A.M., 2010. Predictive and Prognostic Protein

Biomarkers in Epithelial Ovarian Cancer:

Recommendation for Future Studies. Cancers, 2(2),

pp.913–954.

Luporsi, E. et al., 2012. Ki-67: Level of Evidence and

Methodological Considerations for Its Role in The


59

Clinical Management of Breast Cancer: Analytical and

Critical Review. Breast Cancer Research and Treatment,

132(3), pp.895–915.

Oemiati, R., Rahajeng, E. & Kristanto, A.Y., 2011.

Prevalensi Tumor dan Beberapa Faktor yang

Mempengaruhinya di Indonesia. Buletin Penelitian

Kesehatan, 39(4), pp.190-204.

Paunesku, T. et al., 2001. Proliferating Cell Nuclear

Antigen (PCNA): Ringmaster of The Genome.

International journal of radiation biology, 77(10),

pp.1007–1021.

Pectasides, D., Pectasides, E., Psyrri, A.,

Economopoulos, T., 2006. Treatment Issues in Clear

Cell Carcinoma of The Ovary: A Different Entity?

Oncologist, 11(10), pp.1089–94.

Reitmaier, M., Rudlowski, C., Biesterfeld S., Rath, W.,

Schröder, W., 2000.[Comparative Studies on The

Biological Significance of The Marker for

Proliferation Ki-67-Antigen and PCNA in Primary

Ovarian Carcinoma]. Zentralbl Gynakol, 122(7),

pp.361-367.

Rubin, E. et al., 2014. The Female Reproductive System.

Essentials of Rubin’s Pathology. 6 edn. Lippincott

Williams & Wilkins, Philadelphia, pp.518-523.

Sajeevan, T. et al., 2014. Immunohistochemical Study of

p53 and Proliferating Cell Nuclear Antigen Expression

in Odontogenic Keratocyst and Periapical Cyst. Journal

of Pharmacy and Bioallied Sciences, 6(5), p.52.

Siegel, R., Naishadham, D. & Jemal, A., 2012. Cancer

Statistics , 2012. CA: A Cancer Journal for

Clinicians, 62(1), pp.10–29.

Tan, D.S.P. & Kaye, S., 2007. Ovarian Clear Cell

Adenocarcinoma: A Continuing Enigma. Journal of

clinical pathology, 60(4), pp.355–360.


60

Thomas, H. et al., 1995. Proliferating Cell Nuclear

Antigen (PCNA) Immunostaining-A Prognostic Factor in

Ovarian Cancer? British journal of cancer, 71(2),

pp.357–362.

Tortora, G. J., & Derrickson, B.H., 2011. The

Reproductive Systems. Principle Anatomy and

Physiology. 13 edn. John Wiley&Sons, Asia, pp.1143-

1150.

Widagdo, R., 2009. Angka Harapan Hidup Penerita Kanker

Ovarium Rumah Sakit Sardjito. Bagian Obstetri dan

Ginekologi FK UGM, Yogyakarta.

Yerushalmi, R., Woods, R., Ravdin, P.M., Hayes, M.M.,

Gelmon, K., 2010. Ki67 in Breast Cancer: Prognostic

and Predictive Potential. The Lancet Oncology, 11(2),

pp.174–183.

Zhong, W. et al., 2008. Ki-67 and PCNA Expression in

Prostate Cancer and Benign Prostatic Hyperplasia.

Clinical and investigative medicine. Medecine clinique

et experimentale, 31(1), pp.E8–E15.


MUSINOSUM, ENDOMETRIOID, DAN SEL JERNIH AMANDA...

Documents

Transcript of MUSINOSUM, ENDOMETRIOID, DAN SEL JERNIH AMANDA...